Cell subsets in blood as a biomarker for Bronchiolitis Obliterans Syndrome (BOS)

Withdrawn

• Conditions: Afstoting na long transplantatie; Bronchiolitis Obliterans Syndrome (BOS) Chronische afstoting na Longtransplantatie; 10027665; 10038716

• Registration Number: NL-OMON45481
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients that underwent a lung transplantation and are receiving follow-up care at the St. Antonius Hosptital. At this point in time there are 10 BOS diagnosed patients receiving follow-up care at the St. Antonius Hosptial. Next to these 10, we want to include 20 lung transplantation patients without BOS. 20 healthy controls will be acquired through corporations like Sanquin.

Exclusion Criteria

1. Not willing to participate
2. Acute rejection after transplantation

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>1. Difference in immune-cell subset composition in peripheral blood, between<br /><br>patients and controls<br /><br>2. Activation marker expression<br /><br>2. Cytokine production capacity<br /><br>3. Differentiation directional </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. Sex<br /><br>2. Age<br /><br>3. Time between tranplantation and BOS diagnosis<br /><br>4. Medication </p><br>